Study: COVID-19 convalescent plasma unlikely to benefit certain ED patients
The National Institutes of Health has halted a clinical trial evaluating the effectiveness of COVID-19 convalescent plasma in emergency department patients with mild-to-moderate COVID-19 symptoms and at least one risk factor for severe COVID-19 after an independent board concluded from the data that the treatment was unlikely to help such patients.
Forty-seven U.S. hospital EDs were participating in the study, which found no significant difference in outcomes for participants who received COVID-19 convalescent plasma or a placebo.
Related News Articles
Headline
Adults age 65 and older are encouraged to receive an updated dosage of the COVID-19 vaccine, the Centers for Disease Control and Prevention announced April 25…
Headline
The Pfizer and Moderna COVID-19 vaccines can cause myocarditis, but do not appear to cause infertility, Guillain-Barré syndrome, Bell’s palsy, thrombosis with…
Headline
The Food and Drug Administration recently granted emergency use authorization for the first over-the-counter home antigen test to detect both flu and COVID-19…
Headline
Centers for Disease Control and Prevention Director Mandy Cohen, M.D., Feb. 28 endorsed a recommendation by its Advisory Committee on Immunization Practices…
Headline
Paxlovid may no longer be distributed with an emergency use label after March 8, the Food and Drug Administration announced. Providers may dispense unexpired…
Headline
A CDC study released Dec. 21 found low COVID-19 and flu vaccination coverage for most adults, and low RSV vaccination coverage for adults aged 60 and…